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It is generally known that fatigue is a common symptom during cancer treatment, and in cancer survivors. However, fatigue was never
studied after diagnosis, before cancer treatment was initiated. This study investigated the prevalence of severe fatigue, and related
factors, in cancer patients before the initiation of treatment. One hundred and seventy-nine patients with various malignancies were
assessed before start of treatment with curative intention, including the Checklist Individual Strength, Sickness Impact Profile, Beck
Depression Inventory Primary Care, Symptom Checklist-90, and six Numeric Rating Scales to measure fatigue, pain and physical
activity. To test which factors contributed to severe fatigue a logistic regression analysis was performed. In total 23.5% patients were
severely fatigued, varying between diagnoses; prostate cancer (14.3%), breast cancer (20.3%), and gastrointestinal cancer (28.1%).
Currently lower physical activity (P¼0.013), more depressive mood (P¼0.014), impaired sleep and rest during the day and night
(P¼0.045), and fatigue 1 year before diagnosis (P¼0.005) contributed to severe fatigue. Relatively large numbers of cancer patients
already experience severe fatigue before initiation of treatment, varying between 14–28%. The factors that contributed to severe
fatigue at this stage were physical activity, depressive mood, impaired sleep and rest, and fatigue 1 year before diagnosis.
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Fatigue is a frequently reported symptom in cancer patients and
when severe, it is a distressing symptom interfering with daily
functioning. Cancer patients experience fatigue at different stages
during their illness. The prevalence of fatigue during cancer
treatment ranges from 25 to 99% in different samples (Servaes
et al, 2002a). After successful cancer treatment severe fatigue
remains problematic in 19–38% of the disease-free cancer
survivors (Servaes et al, 2002a; Prue et al, 2006).
It is generally thought that during the active period of cancer
treatment, symptoms of fatigue arise as a consequence of the
cancer itself, and the treatments patients receive, such as surgery,
chemotherapy and radiotherapy. Other factors are also suggested
to influence fatigue during cancer treatment. Psychological
distress, such as depression, somatisation, anxiety, and also sleep
quality were previously found to relate with fatigue (Servaes et al,
2002a; Respini et al, 2003). It is suggested that the experience of
receiving cancer treatment in itself contributes to the development
of fatigue (Hickok et al, 2005).
Fatigue in cancer patients prior to treatment has seldom been
investigated. Some studies investigated fatigue before start of
chemotherapy (Jacobsen et al, 1999; Ancoli-Israel et al, 2006;
Berger et al, 2007) or radiotherapy (Smets et al, 1998; Stone et al,
2001; Hickok et al, 2005), but looking at these studies more closely
revealed that most patients were not treatment naive. The majority
of patients already received treatment that could have contributed
to fatigue, such as surgery, hormone therapy, or chemotherapy.
Results of three quality of life studies indicate that fatigue might
be problematic in treatment naive cancer patients (Cimprich, 1999;
Handy et al, 2002; Visser et al, 2006). The first study found that
lung cancer patients before surgery reported significantly more
fatigue compared with age-matched control subjects (Handy et al,
2002). Two other studies concluded that fatigue contributed to
increased distress and impaired quality of life in newly diagnosed
cancer patients (Cimprich, 1999; Visser et al, 2006).
Cancer patients report that the period of diagnosis was very
distressing, and research does confirm this. At diagnosis emotional
functioning, anxiety, and sleep problems were the most proble-
matic in patients with oral and oropharyngeal cancer (Shepherd
and Fisher, 2004). In newly diagnosed breast cancer patients,
disturbances in mood states and insomnia were also found, in
addition to loss of concentration (Cimprich, 1999). Thus, newly
diagnosed cancer patients have been studied in the past, but
research specifically aimed at fatigue in this group is lacking.
The first objective of this study is to determine how many cancer
patients report severe fatigue after being diagnosed, but before
initiation of any medical treatment for cancer. If patients do report
severe fatigue, the second objective is to establish which factors
contribute to severe fatigue before cancer treatment, and whether
mood, such as anxiety and depression, and sleep problems
contribute to fatigue.
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Patients and procedure
Patients were recruited from one university hospital and six
regional hospitals in the period from November 2005 until August
2007. Patients were included in this study after being diagnosed
with a primary tumour and before initiation of treatment with
curative intention. Treatment could be surgery, radiotherapy,
chemotherapy, or a combination of these. Patients could
additionally receive hormone therapy. In concordance with
national and regional guidelines of the comprehensive cancer
centre, the curability of a patient with cancer was determined, and
the treatment procedure was chosen. All treatment options were
discussed in the multi disciplinary working party for the specific
tumour group, before the treatment procedure was decided.
Patients in this study were recruited as part of a larger ongoing
intervention study for fatigue during cancer treatment, and
preventing chronic fatigue after finishing cancer treatment. To
minimise drop out and exclusion during the ongoing study,
patients with lung cancer, and head and neck cancer were not
included. Patients were included if they were between 18 and 75
years old, and able to speak, read and write Dutch. Patients were
excluded when having a co-morbidity that could cause fatigue, or
when patients indicated to be severely fatigued for several years or
have been seeking treatment for their fatigue. In addition, patients
who were receiving psychiatric or psychological treatment in the
last 3 months were excluded.
Eligible patients were informed about the study by their
physicians and were asked if a researcher could approach them.
When a specialised cancer unit was present in a hospital, such as a
mamma care or colon care unit, specialised nurses checked for
eligibility and informed patients. When patients agreed the
physician informed the researcher. Patients who agreed to be
approached received written information on the study and were
contacted by telephone by the researcher or a test-assistant. When
patients agreed to participate an appointment was made for the
baseline assessment. The baseline assessment took place, at the
Expert Centre Chronic Fatigue of the Radboud University
Nijmegen Medical Centre, at the hospital where patients would
receive treatment, or at the patients’ home. All participants gave
their written informed consent before baseline assessment. The
ethics committees from all seven involved hospitals gave approval
for the study.
The data presented in this study are based on cancer patients
who were treatment naive, and were assessed before initiation of
treatment.
Instruments Information on age, gender and diagnosis was
provided by the patient’s physician from patients who agreed to
be approached, also from patients who did not participate
eventually. From all participating cancer patients demographic
and medical characteristics were gathered by self-report using
questionnaires. Information on marital status and level of
education were collected as part of the demographic data. The
following information on medical characteristics was obtained:
medication use in the past month, medical history on
co-morbidities, and receiving psychological and psychiatric
treatment during patients’ lifetime.
Fatigue severity was assessed by the subscale fatigue of the
Checklist Individual Strength (CIS) (Vercoulen et al, 1994, 1999).
The CIS is a well-validated instrument among patients with
chronic fatigue syndrome (CFS) and in the working population
(Beurskens et al, 2000; Dittner et al, 2004). The fatigue subscale
consists of eight items scored on a seven-point Likert Scale, with
scores ranging from eight to 56. Based on research with CFS
patients a score of 35 or higher indicate severe fatigue (Vercoulen
et al, 1994). A score between 27 (mean score for healthy adults plus
one s.d.) and 35 indicate a heightened experience of fatigue
(Vercoulen et al, 1999). The CIS was used in earlier research
investigating cancer survivors (Servaes et al, 2001, 2002c, 2003;
Gielissen et al, 2006).
Depression was assessed with the Beck Depression Inventory
Primary Care (BDI-PC) (Beck et al, 1997b). This is a seven item
questionnaire with scores ranging from zero to 21. A score of four
or higher on the BDI-PC is indicative for a clinical depression
(Beck et al, 1997a). The BDI-PC is based on a set of non-somatic
items from the BDI-II (Beck et al, 1996).
Depressive mood was measured with the Symptom Checklist-90
(SCL-90) (Arrindell and Ettema, 1986), subscale depression.
Sixteen items measure depressive mood, with scores ranging from
16 to 80. Higher scores indicated a stronger depressive mood.
Anxiety was measured with the SCL-90 subscale anxiety. Ten
items measure anxiety with scores from 10 to 50. Higher scores
indicated more anxiety.
Quality of nocturnal sleep was measured with the SCL-90
subscale sleep. Three items measure sleep with scores from three
to 15. Higher scores indicated lower quality of sleep. In addition,
the impact of the disease on sleep and rest during the night and
day was measured with the subscale sleep/rest of the Sickness
Impact Profile –8 (SIP) (Bergner et al, 1981; Jacobs et al, 1990).
Higher scores on this subscale was an indication of more
impairment on sleep/rest. Seven items measured impairments on
sleep/rest, with scores ranging from zero to 499.
Physical activity was measured with an 11-point Numeric Rating
Scale (NRS) ranging from zero to 10. Patients were asked how
physically active they were in the period since diagnosis. Zero
indicated ‘not physically active’ and 10 ‘physically very active’.
Pain was also measured with an 11-point NRS. Patients were
asked how much pain they had experienced in the period since
diagnosis, on a scale from zero to 10. Zero indicated ‘no pain’ and
ten ‘very much pain’.
Patients were asked additionally to indicate their level of fatigue,
physical activity, and pain before diagnosis retrospectively, 1 year
before diagnosis and 3 years before diagnosis. Thus, in total six
11-point NRS’ were used, ranging from zero to 10.
Statistical analysis
All data analysis was performed with SPSS (version 14.0).
Differences between participating and non-participating cancer
patients were tested with w
2. For the first objective descriptive
statistics were used to describe demographic characteristics of
treatment naive cancer patients, and the data on the presence of
severe fatigue. Differences on demographic and medical char-
acteristics between severely and non-severely fatigued cancer
patients were tested with w
2. For the second objective, to find the
contributing factors, two steps were taken. The first step was to test
the differences between severely fatigued cancer patients and non-
severely fatigued cancer patients on the contributing factors with a
t-test for independent samples. For the second step a logistic
regression analysis was performed using Stepwise Forward
method. This method was chosen, as it was an exploratory data
analysis. Significant factors found in the first step were put in the
logistic regression as independent variables, with significant
demographic and medical variables as covariates. The dimensions
of depression and sleep were each measured with two instruments,
although measuring different aspects. When both instruments
showed significant results in the first step, the instrument with the
largest significant difference was put into the logistic regression.
Variables that applied to the period before diagnosis were entered
into the first block, and variables that applied to the current period
were entered into the second block. Two persons with missing data
on the BDI-PC or SCL-90 were excluded from the analysis. A two-
sided Po0.05 was considered significant.
Severe fatigue before cancer treatment
MM Goedendorp et al
1409
British Journal of Cancer (2008) 99(9), 1408–1414 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sRESULTS
In total 477 patients agreed to be approached and were contacted
by telephone. During the telephone conversations an additional 82
patients were excluded who did not meet the eligibility criteria.
The most common reasons for exclusion were: having a
co-morbidity that could cause fatigue, and being severely fatigued
for several years. Of the 395 patients who met the inclusion criteria
155 refused to participate for different reasons (see Figure 1). In
total 240 patients participated and completed baseline assess-
ments. The characteristics of participants were compared with
non-participants (see Table 1). Results showed that cancer patients
who refused to participate were significantly older compared to
patients who participated. No differences were found on gender or
diagnosis between participants and non-participants.
Patients usually start with cancer treatment relatively fast after
being diagnosed. As a consequence of this short time span baseline
assessments sometimes took place when cancer treatment had just
started. For example, some breast cancer patients were assessed
after surgery, but before adjuvant radiotherapy or chemotherapy.
Of the 240 participants 61 patients were assessed when their cancer
treatments had just started, but their data were not used in the
analysis. Thus data presented in this study are based on 179 cancer
patients who were treatment naive.
Patient characteristics
Most of the 179 patients were diagnosed with breast cancer or
prostate cancer, 54% were female, and 82% were married (see
Table 2). The mean age of the sample was 56.6 (s.d. 10.9) years, and
the mean education level was 4.1 (s.d. 1.7) ranging between one
and seven (data not shown). No differences were found between
severely and non-severely fatigued cancer patients on demographic
variables such as sex, age, education or marital status, although the
difference between males and females nearly reached significance.
In addition, differences were tested on several medical variables
between severely fatigued cancer patients and non-severely
fatigued cancer patients. No significant differences were found
on current medication use, and on the medical history of
co-morbidities, and receiving psychological or psychiatric treat-
ment in patients’ lifetime (all P40.971) (data not shown).
The presence of severe fatigue in cancer patients before
treatment
In the total sample 23.5% of the cancer patients were severely
fatigued, but this percentage varied between diagnoses (see
Table 2). The presence of severe fatigue was the lowest in patients
with prostate cancer (14.3%), but higher in breast cancer patients
(20.3%). In the group of patients with other tumours the presence
of severe fatigue was the highest (33.3%). When patients with
gastrointestinal cancer were considered as a separate group,
fatigue in this specific group was 28.1%. In patients with other
tumours without gastrointestinal cancer severe fatigue even rose to
38.2%. A significant overall effect of diagnosis on severe fatigue
was found using the w
2 test (P¼0.044). In addition, we tested if the
means of the three diagnosis groups were different on the CIS
using ANOVA, and also a significant overall effect was found
(P¼0.014). Using a post hoc test we tested which of the three
groups (breast cancer (mean 23.5, s.d. 12.4), prostate cancer (mean
19.9, s.d. 12.0), or other tumours including gastrointestinal cancer
(mean 27.1, s.d. 13.9)) differed from each other, and found one
significant difference. Patients with prostate cancer were signifi-
cantly less fatigued compared with the group of patients with other
tumours (P¼0.011) (data not shown).
Contributing factors to severe fatigue before cancer
treatment
In Table 3 the differences on contributing factors between severely
fatigued cancer patients and non-severely fatigued cancer patients
are described. Severely fatigued cancer patients reported to have
Approached
N=477
Did not meet eligibility criteria
N=82
Met eligibility criteria
N=395
Did not participate
N=155
Participants
N=240
Treatment-naive cancer patients
N=179
Resons not to participate*:
Would take too much time: N=45
Living too far away: N=19
Did not feel like participating at this stage: N=33
Other priorities: N=19
Felt the study would not be helpful for them: N=21
Other reasons: N=44
*Some patients gave more than one reason.
Figure 1 Flow chart showing the accrual of patients.
Table 1 Differences between participants and non-participants
Participants Non-participants
Characteristics 240 155
Total (n) Mean (s.d.) Mean (s.d.) P-value
Age (years) 56.8 (11.1) 59.7 (10.9) 0.010
Sex n (%) n (%) 0.219
Male 92 (38.3) 50 (32.3)
Female 148 (61.7) 105 (67.7)
Diagnosis
a 0.310
Breast cancer 109 (45.4) 81 (52.3)
Prostate cancer 57 (23.8) 28 (17.4)
Other tumours 76 (31.7) 47 (30.3)
Gastrointestinal 33 26
Urogenital 16 9
Gynaecological 13 10
Lymphomas 7 0
Sarcoma 3 2
Melanoma 2 0
Thyroid carcinoma 2 0
aThree patients were diagnosed with both bladder and prostate cancer and were
categorised as urogenital tumours of the other tumours. A two-sided Po0.05 was
considered significant.
Severe fatigue before cancer treatment
MM Goedendorp et al
1410
British Journal of Cancer (2008) 99(9), 1408–1414 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
smore fatigue in the period before diagnosis, more pain, and being
less physically active. These differences were significant for both
periods, 1 and 3 years before diagnosis. Severely fatigued cancer
patients also reported currently more pain and being less
physically active, than non-severely fatigued cancer patients. In
addition, they reported significantly more sleeping problems, and
more feelings of depression and anxiety.
The results of the logistic regression are described in Table 4.
Four factors contributed uniquely to severe fatigue in cancer
patients before treatment. First fatigue 1 year before diagnosis
contributed significantly. Three factors of the current period
contributed significantly to severe fatigue. Lower physical activity
contributed the most, followed by depressive mood and impair-
ments on sleep and rest. Two factors, diagnosis and physical
Table 2 Data of demographic variables, diagnosis and presence of severe fatigue
Total sample
Non-severely fatigued
cancer patients
Severely fatigued
cancer patients Difference
a
Characteristics nn (%) n (%) P-value
Total 179 137 (76.5) 42 (23.5)
Sex 0.064
Male 82 68 (82.9) 14 (17.1)
Female 97 69 (71.1) 28 (28.9)
Age (years) 0.237
Younger age group (p57) 88 64 (72.7) 24 (27.3)
Older age group (458) 91 73 (80.2) 18 (19.8)
Education level 0.269
Lower education (p4) 111 88 (79.3) 23 (20.7)
Higher education (44) 68 49 (72.1) 19 (27.9)
Marital status 0.568
Married/cohabiting 146 113 (77.4) 33 (22.6)
Other status (unmarried/divorced/widowed) 33 24 (72.7) 9 (27.3)
Diagnosis
b 0.044
Breast cancer 64 51 (79.7) 13 (20.3)
Prostate cancer 49 42 (85.7) 7 (14.3)
Other tumours 68 46 (67.7) 22 (33.3)
Gastrointestinal 32 23 (71.9) 9 (28.1)
Urogenital 14 6
Gynaecological 10 3
Lymphomas 5 2
Sarcoma 3 1
Melanoma 2 1
Thyroid carcinoma 2 1
aDifference between severely and non-severely cancer patients, tested with w
2.
bTwo patients were diagnosed with both bladder and prostate cancer and were categorized as
urogenital tumours of the other tumours. A two-sided Po0.05 was considered significant.
Table 3 Contributing factors to severe fatigue before cancer treatment tested with a t-test
Factors
Non-severely fatigued
mean (s.d.)
Severely fatigued
mean (s.d.) t d.f. P-value
Period before diagnosis
Fatigue 1 year before diagnosis
a 1.71 (2.43) 3.86 (2.89) 4.786 177 o0.001
Fatigue 3 years before diagnosis 1.32 (2.14) 2.93 (2.67) 3.563 177 0.001
Physical activity 1 year before diagnosis 7.06 (2.34) 6.17 (2.66)  2.094 177 0.038
Physical activity 3 years before diagnosis
a 7.28 (2.24) 6.17 (2.63)  2.711 177 0.007
Pain 1 year before diagnosis 0.89 (1.91) 1.95 (2.68) 2.391 177 0.020
Pain 3 years before diagnosis
a 0.73 (1.66) 1.76 (2.43) 2.577 177 0.013
Current period before cancer treatment
Pain
a 1.28 (2.14) 3.24 (3.04) 3.900 177 o0.001
Anxiety
a 13.1 (3.77) 17.0 (6.91) 3.502 176 0.001
Sleep quality (SCL-sleep) 4.91 (2.23) 6.91 (2.93) 4.061 176 o0.001
Impairments on sleep/rest (SIP-SR)
a 34.7 (46.4) 85.1 (70.4) 4.358 177 o0.001
Physical activity
a 6.66 (2.42) 4.69 (2.37)  4.636 177 o0.001
Depressive mood (SCL-90)
a 20.8 (5.86) 27.5 (9.54) 4.360 176 o0.001
%( n)% ( n)
Clinical depression (BDI-PC)
b 2.9 (4) 17.1 (7) 0.004
aFactors that were put into the logistic regression analysis as separate factors.
bDifference on clinical depression was tested with Fisher’s Exact Test.
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severe fatigue. Anxiety and pain were not part of the logistic
regression.
DISCUSSION
This is the first study specifically aimed at investigating fatigue in
patients who were recently diagnosed with cancer, before initiation
of any treatment for cancer. The first goal of this study was to
establish how many cancer patients report severe fatigue before
receiving treatment. In the whole sample 24% of the cancer
patients were severely fatigued, ranging from 14 to 28%. The
presence of severe fatigue was the lowest in patients with prostate
cancer (14%), but higher in breast cancer patients (20%), and
gastrointestinal cancer patients (28%).
The prevalence of severe fatigue in our study is surprisingly
high, in perspective to results in other samples. Reviewing the
results of seven different studies fatigue in cancer survivors appear
to vary between 16 and 38%, compared with 10–11% in a control
group (Gielissen, 2007). The prevalence of severe fatigue in cancer
survivors with various cancer diagnoses was about 22% (Servaes
et al, 2001, 2002c; Bartsch et al, 2003). Thus severe fatigue in
cancer patients before treatment seems two times as high
compared with people without a history of cancer, and reaching
the level of severe fatigue in cancer survivors long after cancer
treatment.
As patients in this study were recruited as part of a larger
intervention study, the question rises if this could be a biased
sample. In the general Dutch population more males are diagnosed
with cancer than females. In addition, breast cancer is the most
common type of cancer, followed by colorectal cancer, lung cancer,
and prostate cancer (Visser et al, 2003). So the sample in this study
does not reflect the incidence and types of cancer in the Dutch
population, as more females were included and prostate cancer
was more common than gastrointestinal cancer in this sample.
These differences cannot be explained from the characteristics of
the patients who refused to participate, as no significant
differences were found between participants and non-participants
on sex and diagnosis. The following reasons might explain these
differences. One reason might be, because this sample is a selected
group of cancer patients who would be treated with curative intent.
Another reason might be that patients with colorectal cancer are
more often diagnosed in an acute phase requesting immediate
treatment, whereas patients with breast or prostate cancer receive
treatment in a more planned manner. Patients diagnosed and
treated in this acute phase were more difficult to approach and to
include into the study. This also explains the small numbers of
patients with testis cancer in this study, who also receive surgery in
an acute phase. The organisation of the recruitment might also
explain the differences between our sample and the Dutch
population. For example, in most hospitals specialised mamma
care units were involved with recruiting patients, which might
explain the large numbers of patients with breast cancer.
The question rose if severe fatigue was more common in this
sample as patients were recruited for an intervention study on
fatigue during cancer treatment. We do not expect that patients
with severe fatigue are over-represented in this sample. Firstly,
physicians excluded patients with co-morbidities that could have
caused fatigue, for example patients with rheumatic arthritis or
heart disease. Secondly, patients were informed that prevention of
severe fatigue was the main goal of the study, and patients who
indicated seeking help for severe fatigue were not included in the
study. Thirdly, although patients were excluded when receiving
psychiatric or psychological treatment in the last 3 months based
on self-report, patients were not excluded based on taking
psychotropic medicines. However, only one participant took
psychotropic medicine, so it is improbable that this is an
explanation for the prevalence of severe fatigue. The prevalence
of severe fatigue might even be underestimated. More patients with
prostate cancer (who are less frequently and severely fatigued), and
less patients with colorectal cancer (who are more often severely
fatigued) participated in this study, compared with the Dutch
population.
Our second goal was to investigate which factors influenced
severe fatigue before cancer treatment, and four factors were
found. More fatigue 1 year before diagnosis, currently lower
physical activity, depressive mood and more impaired sleep and
rest appeared to be related to fatigue prior to treatment. Although
differences were found in the prevalence of severe fatigue among
various groups of diagnoses, results showed that diagnosis did not
uniquely contribute to severe fatigue. In the light of this result,
TNM classification of each tumour was considered not useful.
Further classification would increase the number of subgroups,
making it even harder to demonstrate a potential relationship
between diagnosis and fatigue. The four mentioned factors are
thus stronger related to severe fatigue than diagnosis, and also
stronger than anxiety, pain or physical activity 3 years before
diagnosis.
Lower physical activity was related to fatigue in cancer patients
during treatment (Dimeo et al, 1997; Berger, 1998; Berger and Farr,
1999) and in cancer survivors (Bergner et al, 1981; Servaes et al,
2002c) as previous studies revealed. A new finding is that this
relationship between physical activity and fatigue was now found
in cancer patients before initiation of treatment.
Two studies that investigated the quality of life in newly
diagnosed cancer patients found that sleeping problems affected
patients before cancer treatment (Cimprich, 1999; Shepherd and
Table 4 Contributing factors to severe fatigue
Contributing factors B (SE) Exp b P-value 95% CI
Diagnosis group 0.374
Diagnosis group (1) (breast cancer) 0.783 (0.609) 2.187 0.199 0.663–7.218
Diagnosis group (2) (prostate cancer) 0.270 (0.606) 1.310 0.656 0.399–4.297
Period before diagnosis
Fatigue 1 year before diagnosis 0.218 (0.077) 1.244 0.005 1.070–1.446
Physical activity 3 years before diagnosis 0.020 (0.111) 1.020 0.855 0.822–1.267
Current period before treatment
Depressive mood (SCL-90) 0.076 (0.031) 1.079 0.014 1.015–1.147
Impairments on sleep/rest (SIP-SR) 0.008 (0.004) 1.008 0.045 1.000–1.015
Physical activity  0.284 (0.115) 0.752 0.013 0.601–0.943
Constant  2.986 (1.040) 0.051 0.004
(R
2 was 0.274 (Cox & Snell) and 0.412 (Nagelkerke)). A two-sided Po0.05 was considered significant.
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sFisher, 2004); however, it remained unclear which aspects of sleep
were affected. Looking at our results on the subscale sleep/rest of
the SIP more closely revealed four differences between severely
and non-severely fatigued cancer patients. Severely fatigued cancer
patients indicated to sleep less at night, sleep or nap more during
the day, sit during much of the day, and lie down to rest more
often during the day. Thus, not only the nocturnal sleep was
affected in severely fatigued cancer patients, but their daily sleep
and rest was affected too.
One of the symptoms of clinical depression can be fatigue.
However, the prevalence of clinical depression in our sample is low
(6.2%) and within the normal range of the adult Dutch population
(5.7–6.6%) (RIVM, 2007). Thus, clinical depression cannot be an
explanation for the high prevalence of severe fatigue in this study.
In addition our results showed the necessity to distinguish clinical
depression from depressive mood, with the latter clearly being a
mood state. Although no structured psychiatric interview was used
to diagnose mood disorders.
Fatigue 1 year before diagnosis was evaluated retrospectively by
patients, and not measured at that specific time. This evaluation
probably reflects patients’ recollection of fatigue 1 year before
diagnosis, rather than actual fatigue at that time.
Contrary to what was expected anxiety was not found as a
fatigue-contributing factor. Receiving the diagnosis cancer can
inflict strong feelings of anxiety (Stanton and Snider, 1993;
Cimprich, 1999), although these high levels appeared to decrease
within 2 weeks (Shepherd and Fisher, 2004). This trend was also
found in patients receiving chemotherapy. High level of anxiety
prior to chemotherapy decreased as soon as individuals started
treatment (Jacobsen et al, 1993; Trask et al, 2003). Thus, feelings of
anxiety are a common reaction on being diagnosed with cancer,
and the prospect of receiving chemotherapy, but feeling of anxiety
are not related to severe fatigue in treatment naive cancer patients.
No previous research was done to investigate the relationship
between fatigue and pain in treatment naive cancer patients, but
no evidence was found that pain contributed to severe fatigue in
this study.
One of the limitations in this study is the reliance on cross-
sectional data. Therefore, we cannot make any claims for causality
between fatigue and the related factors, impaired sleep and rest,
depressive mood, and physical activity.
In this study questionnaires were used to measure physical
activity, but asking people to estimate their level of
physical activity has its limitations. Previous research showed that
there is a lack of correspondence between self-reported
physical activity and objective physical activity (Vercoulen et al,
1997; Servaes et al, 2002b). Probably the perception of physical
activity does not always reflect the actual level of physical activity.
Thus in our study it is more likely that the perceived level
of physical activity was related to severe fatigue rather than the
actual level.
In summary, it is generally known that most cancer patients will
experience fatigue during treatment, but fatigue in treatment naive
cancer patients was not previously investigated. This study showed
that a large number of cancer patients already experience severe
fatigue before initiation of cancer treatment. One might expect that
the course of fatigue during and after cancer treatment could be
different for patients with severe fatigue or patients without severe
fatigue before cancer treatment. In addition, it remains a question
if patients with severe fatigue before cancer treatment should
receive a kind of early fatigue intervention at this stage. These will
be topics for future research.
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